Divi's Lab, INE361B01024

Divi's Lab Stock - Long-term growth story in Indian pharma

20.06.2026 - 15:10:42 | ad-hoc-news.de

Divi's Lab stock remains a key Indian pharma name for long-term investors. With no fresh corporate news today, the focus shifts to its business model, margins and positioning in global active pharmaceutical ingredients.

Divi's Lab, INE361B01024
Divi's Lab, INE361B01024

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:05 CET. Details in the imprint.

Divi's Lab (INE361B01024) is one of India's most closely watched specialty pharma manufacturers. With no new filings or major headlines today, investors are revisiting the company's long-term earnings drivers and positioning in active pharmaceutical ingredients.

Go deeper

Background and price data on Divi's Lab

All news, filings and market data on Divi's Lab stock are collected on the ad-hoc-news topic page and the company's own investor relations site.

How Divi's Lab earns its money

Divi's Lab focuses on custom synthesis and generic active pharmaceutical ingredients (APIs) for global innovators and generic drug makers, with export-heavy revenue from regulated markets like the United States and Europe.

According to its public profile and exchange data, the company operates in the healthcare and pharmaceuticals space and is classified under pharmaceuticals and drugs on Indian stock platforms.

Long-term growth drivers in APIs

The structural case for Divi's Lab rests on continued outsourcing of complex chemistry to India, growing demand for specialty APIs and vitamins, and regulatory pressure on global pharma to secure diversified, compliant supply chains.

Market data providers list Divi's Lab within the healthcare sector, reflecting its role as a supplier to a broad set of global pharmaceutical customers rather than a consumer-brand drug maker.

What the company sells

Divi's Lab generates most of its revenue from custom synthesis projects and a portfolio of generic APIs and intermediates used in therapies such as antivirals, central nervous system drugs and vitamins, serving large global pharmaceutical companies.

Where the stock trades today

Shares of Divi's Lab (INE361B01024) last traded on the National Stock Exchange of India at around ?6,749.50 as of 06/20/2026, 06:05 IST.

Key facts on Divi's Lab stock

  • Company: Divi's Laboratories Ltd
  • ISIN: INE361B01024
  • WKN: 532488
  • Ticker: DIVISLAB
  • Venue: NSE
  • Price (as of 06/20/2026, 06:05 IST): 6,749.50 INR
  • Market cap: 1,79,000.00 crore INR (as of 06/20/2026)
  • Sector / Industry: Healthcare - Pharmaceuticals & Drugs
  • Index membership: Nifty 50
  • Next earnings date: not officially scheduled

More on Divi's Lab stock on social media

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.

en | INE361B01024 | DIVI'S LAB | boerse | 69590503 | bgmi